ASLAN Completes Series A Funding For $12 Mn; Eyes More Financing Options With Spiraling Portfolio
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Singapore-based discovery research start-up ASLAN Pharmaceuticals reached a major milestone as it completed its Series A financing of $12 million. The fund will be utilized to develop the first set of in-licensed compounds by ASLAN
You may also be interested in...
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
Singapore's Aslan Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Focused on in-licensing early-stage compounds to take advantage of efficiencies of running trials in Asia, Aslan previously obtained a HER2/EGFR inhibitor from Array BioPharma.